Inhibition of PREX1 Reverses Enzalutamide Resistance in Castration-Resistant Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Castration-resistant prostate cancer (CRPC) frequently develops resistance to enzalutamide therapy.
• Understanding the molecular mechanisms of enzalutamide resistance is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the mechanisms of enzalutamide resistance in CRPC.
• To explore the role of phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchanger 1 (PREX1) in mediating CRPC resistance.

Main Methods:

• RNA sequencing and gene expression profiling.
• Cell proliferation, colony formation, and invasion assays.
• Western blotting, phosphoprotein profiling, and in vivo tumor xenograft models.

Main Results:

• Enzalutamide-resistant CRPC cells showed upregulation of PREX1 and activation of cancer migration pathways.
• PREX1 knockdown reduced cell proliferation, colony formation, and migration by inhibiting EGFR signaling.
• Tumor growth was significantly reduced in vivo following PREX1 knockdown.

Conclusions:

• PREX1 plays a critical role in mediating enzalutamide resistance in CRPC.
• PREX1 represents a potential therapeutic target to overcome drug resistance and enhance treatment efficacy in CRPC.